Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients with Myelofibrosis: A Case Series

Myelofibrosis (MF) is one of the classic myeloproliferative neoplasms (MPNs) and can occur de novo or following transformation from polycythemia vera (PPV MF) or essential thrombocythemia (PET MF). It can be associated with constitutional symptoms and splenomegaly, both of which can greatly affect quality of life. The only curative option for MF is allogeneic stem cell transplantation. Studies have shown JAK2 inhibitors such as ruxolitinib are effective in reducing both splenomegaly and symptom burden.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 27, 2018 Category: Hematology Authors: Aaron Gerds, Derrick Su, Anastasia Martynova, Benjamin Pannell, Sudipto Mukherrjee, Caitlin O ’Neill, Mikkael Sekeres, Casey O’Connell Tags: Original Study Source Type: research